Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial - PubMed (original) (raw)
Clinical Trial
. 2001 Sep 22;358(9286):966-70.
doi: 10.1016/s0140-6736(01)06103-7.
Affiliations
- PMID: 11583750
- DOI: 10.1016/s0140-6736(01)06103-7
Clinical Trial
Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial
G H Mickisch et al. Lancet. 2001.
Abstract
Background: Surgery is the main treatment for localised renal cell carcinoma, but use of radical nephrectomy for metastatic disease is highly controversial. We aimed to establish whether radical nephrectomy done before interferon-alfa-based immunotherapy improved time to progression and overall survival (primary endpoints) compared with interferon alfa alone.
Methods: We included 85 patients from June, 1995, to July, 1998: two (one per group) were ineligible. 42 of the 83 participants were randomly assigned combined treatment (study group) and 43 immunotherapy alone (controls). All patients had metastatic renal-cell carcinoma that had been histologically confirmed and was progressive at entry. In study patients, surgery was done within 4 weeks of randomisation, and immunotherapy (5x10(6) IU/m(2) subcutaneously three times per week) started 2-4 weeks later. In controls, immunotherapy was started within 1 working day of randomisation. Follow-up visits were monthly. All analyses were by intention to treat.
Findings: 40 (53%) of 75 patients received at least 16 weeks of interferon-alfa treatment, which was also the median duration of treatment. Time to progression (5 vs 3 months, hazard ratio 0.60, 95% CI 0.36-0.97) and median duration of survival were significantly better in study patients than in controls (17 vs 7 months, 0.54, 0.31-0.94). Five patients responded completely to combined treatment, and one to interferon alfa alone. Dose modification was necessary in 32% of patients, most commonly because of non-haematological side-effects.
Interpretation: Radical nephrectomy before interferon-based immunotherapy might substantially delay time to progression and improve survival of patients with metastatic renal cell carcinoma who present with good performance status.
Comment in
- Back to nephrectomy for patients with metastatic renal cancer.
Klotz L. Klotz L. Lancet. 2001 Sep 22;358(9286):948-9. doi: 10.1016/S0140-6736(01)06113-X. Lancet. 2001. PMID: 11583744 No abstract available.
Similar articles
- Immunotherapy for advanced renal cell cancer.
Coppin C, Porzsolt F, Awa A, Kumpf J, Coldman A, Wilt T. Coppin C, et al. Cochrane Database Syst Rev. 2005 Jan 25;(1):CD001425. doi: 10.1002/14651858.CD001425.pub2. Cochrane Database Syst Rev. 2005. PMID: 15674877 Updated. Review. - Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer.
Flanigan RC, Salmon SE, Blumenstein BA, Bearman SI, Roy V, McGrath PC, Caton JR Jr, Munshi N, Crawford ED. Flanigan RC, et al. N Engl J Med. 2001 Dec 6;345(23):1655-9. doi: 10.1056/NEJMoa003013. N Engl J Med. 2001. PMID: 11759643 Clinical Trial. - Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial.
Escudier B, Pluzanska A, Koralewski P, Ravaud A, Bracarda S, Szczylik C, Chevreau C, Filipek M, Melichar B, Bajetta E, Gorbunova V, Bay JO, Bodrogi I, Jagiello-Gruszfeld A, Moore N; AVOREN Trial investigators. Escudier B, et al. Lancet. 2007 Dec 22;370(9605):2103-11. doi: 10.1016/S0140-6736(07)61904-7. Lancet. 2007. PMID: 18156031 Clinical Trial. - Interferon alfa-2a versus combination therapy with interferon alfa-2a, interleukin-2, and fluorouracil in patients with untreated metastatic renal cell carcinoma (MRC RE04/EORTC GU 30012): an open-label randomised trial.
Gore ME, Griffin CL, Hancock B, Patel PM, Pyle L, Aitchison M, James N, Oliver RT, Mardiak J, Hussain T, Sylvester R, Parmar MK, Royston P, Mulders PF. Gore ME, et al. Lancet. 2010 Feb 20;375(9715):641-8. doi: 10.1016/S0140-6736(09)61921-8. Epub 2010 Feb 10. Lancet. 2010. PMID: 20153039 Free PMC article. Clinical Trial. - The timing of immunotherapy and nephrectomy in multimodality treatment of metastatic renal cell carcinoma.
Bex A, Horenblas S, de Gast GC. Bex A, et al. Technol Cancer Res Treat. 2003 Jun;2(3):205-10. doi: 10.1177/153303460300200304. Technol Cancer Res Treat. 2003. PMID: 12779351 Review.
Cited by
- Targeting the Adenosine A2A Receptor as a Novel Therapeutic Approach for Renal Cell Carcinoma: Mechanisms and Clinical Trial Review.
Chen TY, Chang YC, Yu CY, Sung WW. Chen TY, et al. Pharmaceutics. 2024 Aug 27;16(9):1127. doi: 10.3390/pharmaceutics16091127. Pharmaceutics. 2024. PMID: 39339165 Free PMC article. Review. - Can Cytoreductive Nephrectomy Improve Outcomes of Nivolumab Treatment in Patients with Metastatic Clear-Cell Renal Carcinoma?
Ocak B, Sahin AB, Ertürk I, Korkmaz M, Erdem D, Cakıroglu U, Karaca M, Dirican A, Olmez OF, Goktas Aydın S, Gökyer A, Kücükarda A, Gülmez A, Yumuk PF, Demircan NC, Oyman A, Sakalar T, Karatas F, Demir H, Yasin AI, Deligonul A, Dakiki B, Goktug MR, Avcı O, Tacar SY, Turhal NS, Deniz GI, Kacan T, Cubukcu E, Evrensel T. Ocak B, et al. Curr Oncol. 2024 Sep 4;31(9):5195-5205. doi: 10.3390/curroncol31090384. Curr Oncol. 2024. PMID: 39330012 Free PMC article. - Impact of Timing of Immunotherapy and Cytoreductive Nephrectomy in Metastatic Renal Cell Carcinoma: Real-World Data on Survival Outcomes from the CKCis Database.
Park CL, Moria FA, Ghosh S, Wood L, Bjarnason GA, Bhindi B, Heng DYC, Castonguay V, Pouliot F, Kollmannsberger CK, Bosse D, Basappa NS, Finelli A, Fallah-Rad N, Breau RH, Lalani AA, Tanguay S, Graham J, Saleh RR. Park CL, et al. Curr Oncol. 2024 Aug 18;31(8):4704-4712. doi: 10.3390/curroncol31080351. Curr Oncol. 2024. PMID: 39195334 Free PMC article. - Nephron-sparing surgery in metastatic renal cell carcinoma.
Guachetá Bomba JM, García-Perdomo HA. Guachetá Bomba JM, et al. Int Urol Nephrol. 2024 Oct;56(10):3279-3281. doi: 10.1007/s11255-024-04124-3. Epub 2024 Jun 18. Int Urol Nephrol. 2024. PMID: 38888680 No abstract available. - Real-World Impact of Upfront Cytoreductive Nephrectomy in Metastatic Non-Clear Cell Renal Cell Carcinoma Treated with First-Line Immunotherapy Combinations or Tyrosine Kinase Inhibitors (A Sub-Analysis from the ARON-1 Retrospective Study).
Fiala O, Buti S, Bamias A, Massari F, Pichler R, Maruzzo M, Grande E, De Giorgi U, Molina-Cerrillo J, Seront E, Calabrò F, Myint ZW, Facchini G, Kopp RM, Berardi R, Kucharz J, Vitale MG, Pinto A, Formisano L, Büttner T, Messina C, Monteiro FSM, Battelli N, Kanesvaran R, Büchler T, Kopecký J, Santini D, Giudice GC, Porta C, Santoni M. Fiala O, et al. Target Oncol. 2024 Jul;19(4):587-599. doi: 10.1007/s11523-024-01065-w. Epub 2024 May 5. Target Oncol. 2024. PMID: 38704759 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
- 2U10 CA11488-25/CA/NCI NIH HHS/United States
- 2U10 CA11488-28/CA/NCI NIH HHS/United States
- 5U10 CA11488-24/CA/NCI NIH HHS/United States
- 5U10 CA11488-26/CA/NCI NIH HHS/United States
- 5U10 CA11488-27/CA/NCI NIH HHS/United States
- 5U10 CA11488-29/CA/NCI NIH HHS/United States
- 5U10 CA11488-30/CA/NCI NIH HHS/United States
LinkOut - more resources
Full Text Sources
Medical